NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Price Target & More

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics (NASDAQ:HTGM) posted its earnings results on Thursday, May, 10th. The medical research company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.04. The medical research company earned $4.16 million during the quarter, compared to the consensus estimate of $5.24 million. HTG Molecular Diagnostics had a negative net margin of 105.56% and a negative return on equity of 338.96%. View HTG Molecular Diagnostics' Earnings History.

2 brokers have issued 1 year target prices for HTG Molecular Diagnostics' stock. Their predictions range from $7.00 to $7.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $7.00 in the next year. View Analyst Ratings for HTG Molecular Diagnostics.

Some companies that are related to HTG Molecular Diagnostics include Pacific Biosciences (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), pSivida (EYPT), Aethlon Medical (AEMD), Arrayit Corp common stock (ARYC), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

News headlines about HTGM stock have trended somewhat positive recently, Accern reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. HTG Molecular Diagnostics earned a coverage optimism score of 0.13 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 46.58 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

HTG Molecular Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Stifel Financial Corp (0.33%), Northern Trust Corp (0.18%) and New York State Common Retirement Fund (0.17%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.

HTGM stock was acquired by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Northern Trust Corp and New York State Common Retirement Fund. View Insider Buying and Selling for HTG Molecular Diagnostics.

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTGM stock can currently be purchased for approximately $3.61.

HTG Molecular Diagnostics has a market capitalization of $104.69 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.